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Abstract
Background: Treatment of women for high-grade cervical cancer precursors frequently results in clearance of the 
associated high-risk human papillomavirus (hrHPV) infection but the role of treatment among women without hrHPV 
is unknown. We investigated whether cervical cryotherapy reduces newly detected hrHPV infections among HIV-
positive and HIV-negative women who were hrHPV negative when treated.
Methods: The impact of cryotherapy on newly detected hrHPV infections was examined among 612 women of 
known HIV serostatus, aged 35 to 65 years, who were negative for hrHPV DNA, and randomized to either undergo 
cryotherapy (n = 309) or not (n = 303). All women underwent repeat hrHPV DNA testing 6, 12, 24, and 36 months later.
Results: Among 540 HIV-negative women, cryotherapy was associated with a significant reduction in newly detected 
hrHPV infections. Women in the cryotherapy group were 55% less likely to have newly detected hrHPV than women in 
the control group (95% CI 0.28 to 0.71). This association was independent of the influence of changes in sexual 
behaviors following therapy (adjusted hazards ratio (HR) = 0.49, 95% CI 0.29 to 0.81). Among 72 HIV-positive women, 
similar reductions were not observed (HR = 1.10, 95% CI 0.53 to 2.29).
Conclusions: Cervical cryotherapy significantly reduced newly detected hrHPV infections among HIV-negative, but 
not HIV-positive women. These results raise intriguing questions about immunological responses and biological 
mechanisms underlying the apparent prophylactic benefits of cryotherapy.
Background
Human papillomavirus (HPV), the causative agent of cer-
vical cancer, is the most common sexually transmitted
infection worldwide. Approximately 40% of women
become infected with HPV within 2 years of initiating
sexual intercourse, and nearly all women are infected at
some point in their lifetime [1-5]. A small percentage of
women infected with high-risk types of HPV (hrHPV)
develop cervical intraepithelial neoplasia (CIN), which
can act as a precursor to invasive cervical cancer. Multi-
ple techniques are used to screen for and treat CIN
lesions and early stage cervical cancers. Most developed
countries have fairly extensive screening programs that
primarily utilize cervical cytology as the screening
method. Cytology-positive women are usually evaluated
with colposcopy and if a high-grade CIN lesion is identi-
fied, undergo treatment using a variety of methods that
include both excisional and ablative techniques [6].
Unfortunately, this approach to cervical cancer preven-
tion has proven difficult to implement and sustain in
many low-resource settings. To address this disparity,
novel screen and treat strategies, in which women are
screened using a non-cytology-based method and all
screen-positive women undergo cryotherapy, have been
developed.
One of the more controversial aspects of 'screen and
treat' cervical cancer prevention strategies is that a large
number of women without high-grade CIN are screen
positive and will undergo cryotherapy using this
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Page 2 of 9approach. However, there are few data to indicate that
cryotherapy of women without high-grade CIN is harm-
ful and there is both a theoretical basis, as well as limited
data, to suggest that 'overtreatment' may actually provide
marginal beneficial to some patients. It is now widely rec-
ognized that the successful treatment of CIN lesions
using either excisional or ablative methods frequently
results in women becoming hrHPV negative [7].
Although the mechanism responsible for this clearance is
unknown, it is presumably mediated by immunological
mechanisms as opposed to simple elimination of HPV-
infected tissue. However, the effects of treatment on
women without lesions are unclear. It is possible that the
same mechanisms that cause clearance of hrHPV after
cryotherapy in women with high-grade CIN may result in
a prophylactic benefit against subsequent acquisition
and/or reactivation of hrHPV infections.
The randomized clinical trial of two different screen
and treat approaches that we recently conducted in South
Africa provided a unique opportunity to evaluate
whether or not cryotherapy has a prophylactic benefit for
the acquisition/reactivation of hrHPV infections among
women free of hrHPV at baseline.
Methods
Study design
This is a secondary analysis of data collected as part of a
randomized clinical trial assessing the safety and efficacy
of screen and treat [8]. The primary analyses have been
published previously [8]. The current analysis describes
hrHPV acquisition/reactivation over a 36-month period
of time among a cohort of 612 women who were hrHPV
negative and who were randomized to either undergo
cryotherapy or to be followed without treatment unless a
CIN 2,3 lesion was identified. This analysis was possible
since the larger trial evaluated two different screen and
treat strategies. In one arm all HPV positive women
underwent cryotherapy. In the other arm, all visual
inspection with acetic acid (VIA) positive women under-
went cryotherapy. The third arm of the trial consisted of a
control group of women, none of whom, regardless of
their HPV or VIA test results, received cryotherapy.
Therefore, we can compare hrHPV negative women in
the VIA-based arm who were VIA positive and under-
went cryotherapy (n = 309) with similar hrHPV negative
women in the control arm who also were VIA positive
but did not undergo cryotherapy (n = 303) (Figure 1).
Study population
All participants were previously unscreened women, aged
35 to 65 years, recruited through community education
and outreach activities focused on cervical cancer pre-
vention in Khayelitsha, Cape Town, South Africa between
June 2000 and December 2002. All participants provided
written informed consent and the study was approved by
the Institutional Review Boards of Columbia University
and the University of Cape Town.
Study procedures and follow-up
All women had cervical samples collected for hrHPV
testing and underwent the VIA screening test at baseline
prior to randomization. HrHPV testing used the Hybrid
Capture 2 DNA assay (Digene Corporation, Gaitherburg,
MD, USA) and probes for 13 'high carcinogenic risk' HPV
types as previously described [8]. Samples were consid-
ered positive for high-risk HPV DNA if ≥ 1 pg HPV
DNA/ml was detected. A positive VIA test was defined as
any acetowhite lesion and no attempt was made to differ-
entiate the acetowhitening of metaplasia from cervical
intraepithelial neoplasia. Cervical specimens were also
obtained for molecular testing for Neisseria gonorrhoeae
and Chlamydia trachomatis (Hybrid Capture for CT/GC,
Digene). Liquid-based cervical cytology (ThinPrep Pap
Test, Cytyc Corporation, MA, USA) was also performed.
All women received counseling for confidential HIV
serotesting and anonymous HIV serotesting at each visit.
HIV serotesting was performed using the Abbott HIV 1/2
g 0 Kit on the Abbott AXSYM system (Abbott, Chicago,
IL, USA); positive results were confirmed using the
Vironsticka HIV uniform 2 plus 0 kit (Organon Teknika,
Durham, NC, USA). Questionnaires, including sociode-
mographic, clinical and sexual behavior questions, were
administered at each visit.
Women were scheduled for a return visit 2-6 days after
the initial examination and, if eligible for randomization,
were randomized to one of the three groups. Women ran-
domized to receive cryotherapy had the treatment pro-
vided by a trained nurse using N2O2 and a standard
cryosurgical unit (Wallach Surgical Devices, Orange, CT,
USA) using a 3-min freeze, thaw, and second 3-min
freeze. A complete description of the initial examination
procedures and randomization schema has been pub-
lished previously [8].
After treatment, women were instructed to abstain
from vaginal intercourse, douching or using any intravag-
inal products for 4 weeks and given both male and female
condoms to use in the event they did not abstain. Women
were asked to return to the clinic 4 weeks later, at which
time a questionnaire was administered that focused on
potential side effects and complications of cryotherapy
and recent sexual activity. All women included in the cur-
rent analysis were asked to return to the clinic at 6, 12, 24,
and 36 months. At these visits hrHPV testing was
repeated and all women underwent a colposcopic exam
with endocervical curettage and biopsy of all acetowhite
lesions. Clinicians performing the colposcopy were
blinded to all HPV and cytology results. All women with
CIN grade 2 or greater (CIN 2+) detected on biopsy at
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cal excision procedure (LEEP) and exited the study [8].
Statistical analysis
Kaplan-Meier methods were used to describe the cumu-
lative probability of testing positive for high-risk HPV
DNA among women in the two groups [9]. A log-rank
test was used to compare survival curves between the
groups. Analyses were stratified by HIV status ascer-
tained over 36 months since HPV acquisition/reactiva-
tion rates are known to differ substantially by HIV status
[10,11]. In an attempt to distinguish reactivated from
newly acquired infections, we stratified by any reported
sexual activity during the month prior to enrolment or at
1 or 6 months after enrolment. Sexual activity during the
month prior to initial enrolment was taken into consider-
ation because the time from initial exposure to HPV and
active production of virus is approximately 3 weeks [12].
Sexual activity beyond 6 months could not be taken into
consideration because detailed sexual histories were not
collected at 12, 24, and 36 months.
Cox regression models were fitted to evaluate the effect
of cryotherapy on HPV acquisition/reactivation, using a
discrete method for treatment of ties [9], and hazard
ratios (HRs) were reported to measure the association.
Age, C. trachomatis/N. gonorrhoeae infection at enrol-
ment, age at first sexual intercourse, and the lifetime
number of sexual partners were examined as potential
confounders. In addition, as women were encouraged to
refrain from sexual activity or condom use for 4 weeks
following treatment, and sexual activity is strongly associ-
ated with HPV acquisition, variables for sexual activity
and condom use at 4 weeks and 6 months were included
in the multivariate model. These analyses were also strat-
ified by HIV serostatus. We also performed these analy-
ses only among women with a normal baseline
cytological diagnosis in order to exclude those with
potentially false negative HPV results at baseline.
Results
Of the 658 women who were hrHPV negative eligible for
this analysis, 612 (93%) had HPV results available for at
least 1 follow-up visit and were included in the analysis.
Among the HIV-negative women (n = 271 in the cryo-
therapy arm and 269 in the control arm), none of the
baseline characteristics differed significantly by study
arm (Table 1). Among the HIV-positive women (n = 38 in
the cryotherapy arm and n = 34 in the control arm), those
in the cryotherapy arm were significantly less likely than
controls to report ≥ 5 sexual partners in their lifetime
(45% vs 71%, P = 0.027), but there was no significant dif-
ference in the reported number of sexual partners during
the month prior to enrolment (3% ≥ 2 in both arms), mar-
ital status (34% vs 35% married), or any other baseline
characteristic.
Overall, among HIV-negative women, cryotherapy was
associated with a substantial reduction in the rate of
newly detected HPV infections (P = 0.0004), and the
crude HR was 0.45 (95% CI 0.28 to 0.71) (Figure 2a, Table
Figure 1 Flowchart of study design and sampling scheme. (a) All women also received cytology prior to randomization, but only the visual in-
spection with acetic acid (VIA) result and randomization arm determined whether cryotherapy was performed. (b) All women underwent colposcopy/
biopsy at 6, 12, 24, and 36 months; if biopsy-confirmed CIN2+ was detected, women were treated with loop electrosurgical excision procedure (LEEP) 
and exited the study.
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Page 4 of 9Table 1: Baseline sociodemographic characteristics and risk factors for cervical disease at enrolment
No. of subjects (%)
HIV negative HIV positive
Cryotherapy arm, (n = 271) Control arm, (n = 269) Cryotherapy arm, (n = 38) Control arm, (n = 34)
Age, years:
35-39 110 (40.6) 114 (42.4) 19 (50.0) 21 (61.8)
40-49 124 (45.8) 116 (43.1) 18 (47.4) 9 (26.5)
50-65 37 (13.7) 39 (14.5) 1 (2.6) 4 (11.8)
Education:
No school 28 (10.3) 28 (10.4) 3 (7.9) 3 (8.8)
Some primary school 103 (38.0) 98 (36.4) 13 (34.2) 11 (32.4)
Some high school 108 (39.9) 103 (38.3) 17 (44.7) 13 (38.2)
High school graduate 32 (11.8) 40 (14.9) 5 (13.2) 7 (20.6)
Currently employed 73 (26.9) 70 (26.0) 10 (26.3) 3 (8.8)
Married 141 (52.0) 150 (55.8) 13 (34.2) 12 (35.3)
Age < 16 years at first 
sexual intercourse
98 (36.2) 102 (37.9) 12 (31.6) 13 (38.2)
≥ 5 Lifetime sex partners 84 (31.0) 82 (30.5) 17 (44.7)a 24 (70.6)a
≥ 2 Sex partners during 
previous month
3 (1.1) 4 (1.5) 1 (2.6) 1 (2.9)
Current smoker 21 (7.8) 19 (7.1) 6 (15.8) 4 (11.8)
Current contraceptive use:
Injectable 57 (21.0) 44 (16.4) 10 (26.3) 9 (26.5)
Oral 10 (3.7) 5 (1.9) 0 2 (5.9)
No. of live births:
None 5 (1.9) 10 (3.7) 0 3 (8.8)
1-4 181 (66.8) 184 (68.4) 29 (76.3) 24 (70.6)
≥ 5 85 (31.4) 75 (27.9) 9 (23.7) 7 (20.6)
Cytologic abnormality 
(ASCUS or greater)
15 (5.5) 20 (7.4) 2 (5.3) 3 (8.8)
Chlamydia trachomatis or 
Neisseria gonorrhoeae
16 (5.9) 13 (4.8) 6 (15.8) 2 (5.9)
Trichomonas vaginalis 30 (11.1) 25 (9.3) 3 (7.9) 4 (11.8)
aP value < 0.05 for comparisons between the cryotherapy and control group.
ASCUS = atypical squamous cells of undetermined significance.
2). The rates of newly detected HPV infections only
diverged between the two groups after 6 months of fol-
low-up and by 36 months, the cumulative rate of new
detection of HPV infection among women in the cryo-
therapy arm was 11.2% versus 24.8% in the control arm.
Among HIV-positive women, there was no difference in
newly detected HPV infection in those receiving cryo-
therapy at any time point. After 36 months the cumula-
tive newly detected high-risk HPV infection rates was
53.7% versus 50.5% (HR = 1.10, 95% CI 0.53 to 2.29) (Fig-
ure 2b, Table 2). The associations between cryotherapy
and newly detected HPV infection were significantly dif-
ferent by HIV status (Pinteraction = 0.044).
In an attempt to distinguish reactivation from a newly
acquired infection, analyses were stratified by either any
reported sexual activity 1 month before baseline, or at 1
and 6 months after baseline (Table 2). As more than 90%
of the study sample reported sexual activity during this
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Page 5 of 9Table 2: Cumulative probability of human papillomavirus (HPV) acquisition/reactivation among HIV-positive and HIV-
negative women with and without cryotherapy
Cumulative no. with a newly detected HPV infection 
(cumulative%)
6 months 12 months 24 months 36 months P value for log-rank 
test
HIV-negative women
Total sample:
Cryotherapy arm (n = 271) 15 (5.5) 21 (7.9) 25 (9.7) 28 (11.2) 0.0004
Control arm (n = 269) 17 (6.3) 30 (11.5) 45 (18.0) 59 (24.8)
Sexual activity reported during 1 month prior to 
enrolment or at 1 or 6 months after enrollment:
Cryotherapy arm (n = 238)a 13 (5.5) 18 (7.7) 22 (9.7) 25 (11.3) 0.002
Control arm (n = 236)b 16 (6.8) 27 (11.8) 42 (19.4) 56 (27.2)
No sexual activity reported during 1 month prior to 
enrollment and at 1 and 6 months after enrollment:
Cryotherapy arm (n = 31)a 2 (6.5) 3 (10.4) 3 (10.4) 3 (10.4) 0.96
Control arm (n = 29)b 1 (3.5) 3 (10.3) 3 (10.3) 3 (10.3)
HIV-positive women
Total sample:
Cryotherapy arm (n = 38) 9 (23.7) 16 (42.1) 19 (50.8) 20 (53.7) 0.8
Control arm (n = 34)c 7 (20.6) 14 (42.8) 15 (46.6) 16 (50.5)
Sexual activity reported during 1 month prior to 
enrollment or at 1 or 6 months after enrollment:
Cryotherapy arm (n = 33) 8 (24.2) 12 (36.4) 15 (46.4) 16 (49.8) 0.65
Control arm (n = 29)c 7 (24.1) 14 (49.4) 15 (54.0) 15 (54.0)
No sexual activity reported during 1 month prior to 
enrollment and at 1 and 6 months after enrollment:
Cryotherapy arm (n = 5) 1 (20.0) 4 (80.0) 4 (80.0) 4 (80.0) 0.08
Control arm (n = 3) 0 0 0 0
aExcludes two women who could not be classified as either sexual active or inactive during the first 6 months of the study.
bExcludes four women who could not be classified as either sexual active or inactive during the first 6 months of the study.
cExcludes two women who could not be classified as either sexual active or inactive during the first 6 months of the study.
time period, results for sexually active women were simi-
lar to those for the total sample. However, among non-
sexually active, HIV-negative women (31 in cryotherapy
group and 29 in the control group), cryotherapy was not
associated with reduced HPV (P = 0.96). Although this
group is quite small, it is the group in which most newly
detected HPV infections are likely to represent reactiva-
tion of a previously acquired infection. There were too
few sexually inactive HIV-positive (five in the cryother-
apy group and three in the control group) women to eval-
uate the impact of sexual activity.
To further explore the robustness of the observed pro-
tective effect of cryotherapy in HIV-negative women, we
performed stratified analyses by age, marital status, num-
ber of lifetime sexual partners, sexual activity at baseline,
and sexual activity at 1 month following cryotherapy. The
protective effect was consistent in every stratum (HR
ranged from 0.31 to 0.55), except among women older
than 50 years (HR = 0.98, 95% CI 0.29 to 3.28) (Table 3).
After adjusting for age, age at first sexual intercourse,
number of life time sexual partners, C. trachomatis/N.
gonorrhoeae infection at enrolment, sexual behaviors at
months 1 and 6 after enrolment, cryotherapy was still
associated with a 51% reduction in HPV acquisition/reac-
tivation rate among HIV-negative women (adjusted HR =
0.49, 95% CI 0.29 to 0.81), but not among HIV-infected
women (adjusted HR = 1.06, 95% CI 0.35 to 3.18).
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In this screen and treat trial, cryotherapy was associated
with a 50% reduction in the probability of newly detected
hrHPV infection over a 3-year period among women who
were hrHPV negative when treated. This magnitude of
reduction in HPV acquisition/reactivation is similar to
the protective benefits observed among sexually active
women in the randomized trials of the prophylactic HPV
16/18 vaccines [13,14]. These results raise intriguing
questions about the possible mechanisms underlying the
prophylactic benefits of cryotherapy.
A potential confounder to the inference that cryother-
apy is responsible for the reduced rates of hrHPV infec-
tion would be a change in sexual behavior after
cryotherapy. In this study, women undergoing cryother-
apy were encouraged to refrain from sexual intercourse
or, if intercourse occurred, to use condoms for at least 4
weeks following treatment. However, our analyses sug-
gest that the protective effect of cryotherapy on acquisi-
tion/recurrence of hrHPV is unlikely to be explained by a
change in sexual behavior. Since an impact of cryotherapy
on newly detected HPV infections was not observed at
the first visit (6 months) post randomization and only
emerged after 12 months of follow-up, it is unlikely that
acute changes in sexual behavior post cryotherapy are
responsible. Moreover, the stratified analyses showed that
cryotherapy produced the same protective effect regard-
less of a woman's reported sexual behavior. After adjust-
ing for sexual behaviors at 1 month and/or 6 months post
randomization, as well as condom use, cryotherapy was
still associated with a decreased risk of HPV acquisition/
reactivation among HIV-negative women (adjusted HR =
0.49, 95% CI 0.29 to 0.81).
Protective immunity against HPV is poorly understood,
but is thought to result from the interplay of non-specific
innate immunity and antigen-specific adaptive immunity
[15]. HPV utilizes a number of strategies to avoid evoking
the principal innate immunity danger signals. The virus
only expresses non-secreted proteins at a low level and
there is no viremia and limited antigens for systemic pre-
sentation [15]. HPV infection also downregulates major
histocompatibility complex (MHC) class I in the epithe-
lium and cytolysis of HPV-infected keratinocytes does
not lead to inflammation [16]. We speculate that cellular
injury produced by cryotherapy could induce a cascade of
immunological responses by upregulating various cytok-
ines that mediate the innate, cellular, and humoral
immune responses [17]. An adaptive antigen-specific
immunity could then develop following this non-specific
innate immunity stimulation. Alternatively, non-specific
innate immunity evoked by cryotherapy-induced injury
might result in clearance or enhanced suppression of
latent hrHPV infections and produce the observed
effects. Furthermore, if the prophylactic effects of cryo-
therapy on hrHPV acquisition/reactivation are a result of
stimulation of host immune responses, this might explain
why no effect was observed in HIV-positive women. It is
well established that HIV infection increases the likeli-
hood of anogenital HPV infections and that the increased
risk is primarily attributable to the immunological effects
of HIV infection [10,11,18]. Not only have hrHPV acqui-
sition/reactivation rates been shown to be greatest in
HIV-infected women with low CD4+ cell counts, but
HIV infection is also associated with impaired local
mucosal immune response to HPV, including downregu-
lation of cytokines and suppression of proinflammatory
and anti-inflammatory responses [19].
Alternatively, cryotherapy may reduce HPV acquisition
by reducing cervical ectopy [20,21], which is highly asso-
ciated with HPV infection and may specifically increase
the risk of infection with HPV types in the α9 clade, such
as HPV16 [22-24]. Further, by targeting the cervical
transformation zone, where lesions usually arise [25], cry-
otherapy may directly destroy cells harboring latent infec-
tions.
This study has several potential limitations. It was not
possible to determine whether cryotherapy reduced HPV
acquisition or reactivation or both since molecular tests
for hrHPV do not distinguish between the two and nearly
all of the women in our study reported past and current
sexual activity. In the small subset of women reporting no
sexual activity, there was discernible benefit of cryother-
apy on what we presume to be reactivations, but infer-
ence is limited due to the relatively small number of
women in this group. Further, the few infections identi-
fied in this group could potentially be accounted for by
false negative baseline results since the hrHPV assay that
we used detects only relatively high copy numbers of
HPV [26]. We also do not have detailed data on specific
HPV genotypes to determine if they were differentially
affected. Misclassification of sexual activity or HPV
acquisition through other transmission modes (for exam-
ple, hand to genital contact) may also have occurred.
Our study included only a relatively small number of
HIV-positive women. Since most of these women
reported sexual activity we could not distinguish HPV
acquisition from reactivation. HIV-infected women are
known to be at high risk of reactivating established infec-
tions [10,11], thus, a larger sample size may be needed to
detect significant reductions in acquisition.
Our trial design provided a unique opportunity to eval-
uate the prophylactic impact of cryotherapy on hrHPV
acquisition/reactivation in women who did not have
detectable hrHPV DNA when treated. Prior reports on
the effects of various cervical treatment modalities on
hrHPV acquisition/reactivation have been limited by the
fact that treated women had biopsy-confirmed CIN and
were presumably persistently infected with at least one
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women with high-grade CIN undergo treatment, it has
been difficult to find appropriate control groups to deter-
mine the impact of therapy of hrHPV acquisition/reacti-
vation [27]. One recent publication from the ALTS
prospective follow-up trial compared new HPV infec-
tions in HPV-positive women who underwent LEEP and
those who did not [27]. This study found that treatment
of CIN 2,3 with LEEP had little impact on acquisition of
HPV during subsequent 6-month and 21-month periods.
Figure 2 Human papillomavirus (HPV) acquisition/reactivation. HPV acquisition/reactivation among cryotherapy-treated and untreated women 
who tested negative for high-risk HPV DNA but were visual inspection with acetic acid (VIA) positive at baseline.
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slightly reduce the acquisition of hrHPV types, especially
those of the α9 clade. Although our randomized clinical
trial was not specifically designed to address the sub-
group of women that we report on here, the study ran-
domization resulted in two large and comparable groups,
strengthening our inferences that the unexpected obser-
vation may reveal a true biological effect.
Conclusions
Our results suggest that cryotherapy may produce a pro-
phylactic benefit, protecting women against hrHPV
acquisition/reactivation. We hypothesize that this protec-
tive effect is due to the activation of innate or adaptive
immune responses following cryotherapy-induced inju-
ries but immunological studies would be needed to test
this hypothesis and other mechanisms may be involved.
Irrespective of the mechanism of action, our current find-
ings demonstrating a protective effect of cryotherapy on
acquisition/reactivation of hrHPV combined with our
previous findings that cryotherapy reduces the incidence
of CIN 2,3 in hrHPV positive women [8] strongly sup-
ports the promotion of HPV-based screen and treat cer-
vical cancer prevention strategies. These strategies not
only treat prevalent disease but may also reduce the risk
of developing disease over the long term which is an
important benefit especially in populations without
access to routine, repeat cervical cancer screening.
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